O’KeefeSJDBuchmanALFishbeinTM. Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin Gastroenterol Hepatol. 2006;4(1):6-10.
2.
KoffemanGIvan GemertWGGeorgeEKVeenendaalRA. Classification, epidemiology and aetiology. Best Pract Res Clin Gastroenterol. 2003;17(6):879-893.
3.
SpencerAUKovacevichDMcKinney-BarnettM. Pediatric short-bowel syndrome: the cost of comprehensive care. Am J Clin Nutr. 2008;88(6):1552-1559.
4.
GouletOBaglin-GobetSTalbotecC. Outcome and long-term growth after extensive small bowel resection in the neonatal period: a survey of 87 children. Eur J Pediatr Surg. 2005;15(2):95-101.
5.
GodayPS. Short bowel syndrome: how short is too short?Clin Perinatol. 2009;36(1):101-110.
6.
WalesP. Neonatal short bowel syndrome: population-based estimates of incidence and mortality rates. J Pediatr Surg. 2004;39(5):690-695.
7.
Quirós-TejeiraREAmentMEReyenL. Long-term parenteral nutritional support and intestinal adaptation in children with short bowel syndrome: a 25-year experience. J Pediatr. 2004;145(2):157-163.
8.
DiamondIRde SilvaNPencharzPBKimJHWalesPW. Neonatal short bowel syndrome outcomes after the establishment of the first Canadian multidisciplinary intestinal rehabilitation program: preliminary experience. J Pediatr Surg. 2007;42(5):806-811.
9.
WalesPWde SilvaNKimJH. Neonatal short bowel syndrome: a cohort study. J Pediatr Surg. 2005;40(5):755-762.
10.
VantiniIBeniniLBonfanteF. Survival rate and prognostic factors in patients with intestinal failure. Dig Liver Dis. 2004;36(1):46-55.
11.
SondheimerJMCadnapaphornchaiMSontagMZerbeGO. Predicting the duration of dependence on parenteral nutrition after neonatal intestinal resection. J Pediatr. 1998;132(1):80-84.
12.
SpencerAUNeagaAWestB. Pediatric short bowel syndrome: redefining predictors of success. Ann Surg. 2005;242(3):403-409.
13.
DiamondIRStruijsM-Cde SilvaNTWalesPW. Does the colon play a role in intestinal adaptation in infants with short bowel syndrome? A multiple variable analysis. J Pediatr Surg. 2010;45(5):975-979.
14.
PetersJHCBeishuizenAKeurMB. Assessment of small bowel function in critical illness: potential role of citrulline metabolism. J Intensive Care Med. 2011;26(2):105-110.
15.
PapadiaCSherwoodRAKalantzisC. Plasma citrulline concentration: a reliable marker of small bowel absorptive capacity independent of intestinal inflammation. Am J Gastroenterol. 2007;102(7):1474-1482.
16.
CrennPMessingBCynoberL. Citrulline as a biomarker of intestinal failure due to enterocyte mass reduction. Clin Nutr. 2008;27(3):328-339.
17.
DiamantiAPanettaFGandulliaP. Plasma citrulline as marker of bowel adaptation in children with short bowel syndrome. Langenbecks Arch Surg. 2011;396(7):1041-1046.
18.
Bailly-BotuhaCColombVThioulouseE. Plasma citrulline concentration reflects enterocyte mass in children with short bowel syndrome. Pediatr Res. 2009;65(5):559-563.
19.
CrennPCoudray-LucasCThuillierFCynoberLMessingB. Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans. Gastroenterology. 2000;119(6):1496-1505.
20.
JianfengGWeimingZNingL. Serum citrulline is a simple quantitative marker for small intestinal enterocytes mass and absorption function in short bowel patients. J Surg Res. 2005;127(2):177-182.
21.
RhoadsJMPlunkettEGalankoJ. Serum citrulline levels correlate with enteral tolerance and bowel length in infants with short bowel syndrome. J Pediatr. 2005;146(4):542-547.
22.
KhanMMiserachsMHofmeisterB. Degree of parenteral nutrition support correlates with serum citrulline levels in short bowel syndrome. JPEN J Parenter Enteral Nutr. 2010;35:131-139.
23.
LuoMFernández-EstívarizCManatungaAK. Are plasma citrulline and glutamine biomarkers of intestinal absorptive function in patients with short bowel syndrome?JPEN J Parenter Enteral Nutr. 2007;31(1):1-7.
24.
FitzgibbonsSChingYAValimC. Relationship between serum citrulline levels and progression to parenteral nutrition independence in children with short bowel syndrome. J Pediatr Surg. 2009;44(5):928-932.
25.
JeppesenPBSanguinettiELBuchmanA. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 2005;54(9):1224-1231.
26.
JeppesenPBHartmannBHansenBS. Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. Gut. 1999;45(4):559-563.
27.
JeppesenPBHartmannBThulesenJ. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut. 2000;47(3):370-376.
28.
DruckerDJErlichPAsaSLBrubakerPL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A. 1996;93(15):7911-7916.
GleesonMHBloomSRPolakJMHenryKDowlingRH. Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function. Gut. 1971;12(10):773-782.
31.
JeppesenPBGilroyRPertkiewiczM. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut. 2011;60(7):902-914.
32.
NPS Pharmaceuticals. Gattex (teduglutide) meets primary efficacy endpoint in phase 3 pivotal study in patients with adult short bowel syndrome [press release]. http://www.npsp.com/PressReleases/1521514. Accessed June 15, 2011.
33.
AllardyceDB. Cholestasis caused by lipid emulsions. Surg Gynecol Obstet. 1982;154(5):641-647.
34.
ColombVJobert-GiraudALacailleF. Role of lipid emulsions in cholestasis associated with long-term parenteral nutrition in children. JPEN J Parenter Enteral Nutr. 2000;24(6):345-350.
35.
ShinJINamgungRParkMSLeeC. Could lipid infusion be a risk for parenteral nutrition-associated cholestasis in low birth weight neonates?Eur J Pediatr. 2008;167(2):197-202.
36.
CavicchiMBeauPCrennPDegottCMessingB. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med. 2000;132(7):525-532.
37.
FallonEMLeHDPuderM. Prevention of parenteral nutrition-associated liver disease: role of omega-3 fish oil. Curr Opin Organ Transplant. 2010;15(3):334-340.
38.
de MeijerVEGuraKMLeHDMeiselJAPuderM. Fish oil-based lipid emulsions prevent and reverse parenteral nutrition-associated liver disease: the Boston experience. JPEN J Parenter Enteral Nutr. 2009;33(5):541-547.
39.
GuraKMLeeSValimC. Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics. 2008;121(3):e678-e686.
40.
PuderMValimCMeiselJA. Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. Ann Surg. 2009;250(3):395-402.
41.
DiamondIRSterescuAPencharzPBKimJHWalesPW. Changing the paradigm: omegaven for the treatment of liver failure in pediatric short bowel syndrome. J Pediatr Gastroenterol Nutr. 2009;48(2):209-215.
42.
CheungHMLamHSTamYHLeeKHNgPC. Rescue treatment of infants with intestinal failure and parenteral nutrition-associated cholestasis (PNAC) using a parenteral fish-oil-based lipid. Clin Nutr. 2009;28(2):209-212.
43.
ChungPHYWongKKYWongRMS. Clinical experience in managing pediatric patients with ultra-short bowel syndrome using omega-3 fatty acid. Eur J Pediatr Surg. 2010;20(2):139-142.
44.
MaloneFRJavidPJDavisC. Omega-3 Fatty acid supplementation normalizes bilirubin in cholestatic children dependent on parenteral nutrition. J Pediatr Gastroenterol Nutr. 2009;49(Suppl 1):E38-E39. Presented at: North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Annual Meeting, November 12-14, 2009; National Harbor, Maryland.
45.
CalhounAWSullivanJE. Omegaven for the treatment of parenteral nutrition associated liver disease: a case study. J Ky Med Assoc. 2009;107(2):55-57.
46.
EkemaGFalchettiDBoroniG. Reversal of severe parenteral nutrition-associated liver disease in an infant with short bowel syndrome using parenteral fish oil (omega-3 fatty acids). J Pediatr Surg. 2008;43(6):1191-1195.
47.
SodenJSLovellMABrownKPartrickDASokolRJ. Failure of resolution of portal fibrosis during omega-3 fatty acid lipid emulsion therapy in two patients with irreversible intestinal failure. J Pediatr. 2010;156(2):327-331.
48.
FitzgibbonsSCJonesBAHullMA. Relationship between biopsy-proven parenteralnutrition-associated liver fibrosis and biochemical cholestasis in children with short bowel syndrome. J Pediatr Surg. 2010;45(1):95-99.
49.
ParkKTNesporCKernerJJr.The use of Omegaven in treating parenteral nutrition-associated liver disease. J Perinatol. 2011;31(suppl 1):S57-S60.
50.
GouletOAntébiHWolfC. A new intravenous fat emulsion containing soybean oil, medium-chain triglycerides, olive oil, and fish oil: a single-center, double-blind randomized study on efficacy and safety in pediatric patients receiving home parenteral nutrition. JPEN J Parenter Enteral Nutr. 2010;34(5):485-495.
51.
TomsitsEPatakiMTölgyesiA. Safety and efficacy of a lipid emulsion containing a mixture of soybean oil, medium-chain triglycerides, olive oil, and fish oil: a randomised, double-blind clinical trial in premature infants requiring parenteral nutrition. J Pediatr Gastroenterol Nutr. 2010;51(4):514-521.
52.
StrijboschRAMLeeSArsenaultDA. Fish oil prevents essential fatty acid deficiency and enhances growth: clinical and biochemical implications. Metabolism. 2008;57(5):698-707.
53.
de MeijerVELeHDMeiselJAGuraKMPuderM. Parenteral fish oil as monotherapy prevents essential fatty acid deficiency in parenteral nutrition-dependent patients. J Pediatr Gastroenterol Nutr. 2010;50(2):212-218.
54.
CoberMPTeitelbaumDH. Prevention of parenteral nutrition-associated liver disease: lipid minimization. Curr Opin Organ Transplant. 2010;15(3):330-333.
55.
NasrADiamondIRde SilvaNTWalesPW. Is the use of parenteral omega-3 lipid emulsions justified in surgical neonates with mild parenteral nutrition-associated liver dysfunction?J Pediatr Surg. 2010;45(5):980-986.
56.
DannenbergCBierbachURotheABeerJKörholzD. Ethanol-lock technique in the treatment of bloodstream infections in pediatric oncology patients with broviac catheter. J Pediatr Hematol Oncol. 2003;25(8):616-621.
57.
BroomJWoodsMAllworthA. Ethanol lock therapy to treat tunnelled central venous catheter-associated blood stream infections: results from a prospective trial. Scand J Infect Dis. 2008;40(5):399-406.
58.
OnlandWShinCEFustarSRushingTWongW-Y. Ethanol-lock technique for persistent bacteremia of long-term intravascular devices in pediatric patients. Arch Pediatr Adolesc Med. 2006;160(10):1049-1053.
59.
MouwEChessmanKLesherATaggeE. Use of an ethanol lock to prevent catheter-related infections in children with short bowel syndrome. J Pediatr Surg. 2008;43(6):1025-1029.
60.
JonesBAHullMARichardsonDS. Efficacy of ethanol locks in reducing central venous catheter infections in pediatric patients with intestinal failure. J Pediatr Surg. 2010;45(6):1287-1293.
61.
OpillaMTKirbyDFEdmondMB. Use of ethanol lock therapy to reduce the incidence of catheter-related bloodstream infections in home parenteral nutrition patients. JPEN J Parenter Enteral Nutr. 2007;31(4):302-305.
62.
CoberMPKovacevichDSTeitelbaumDH. Ethanol-lock therapy for the prevention of central venous access device infections in pediatric patients with intestinal failure. JPEN J Parenter Enteral Nutr. 2011;35(1):67-73.
63.
WalesPWKosarCCarricatoM. Ethanol lock therapy to reduce the incidence of catheter-related bloodstream infections in home parenteral nutrition patients with intestinal failure: preliminary experience. J Pediatr Surg. 2011;46(5):951-956.
64.
PieroniKNespourCNgMBerquistWKernerJ. Evaluation of ethanol lock therapy in pediatric patients on long-term parenteral nutrition. Presented at: Pediatric Academic Societies and Asian Society or Pediatric Research 2011 Joint Meeting, 2011; Denver, CO. Available at: http://www.abstracts2view.com/pas/view.php?nu=PAS11L1_507.
